Navigation Links
Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
Date:2/26/2009

ell transplant. No unexpected adverse events have been seen. Toxicities were manageable with supportive care and/or dose reductions as required.

Best response (MR or better) and stable disease (no progression for 3 months) to either perifosine + bortezomib (+/-dexamethasone) for patients previously relapsed from or refractory to prior bortezomib treatment was as follows:

    Evaluable Patients         CR        PR        MR       ORR     SD > 3 mos
    Bortezomib Relapsed
     (n=20)                  2   10%   6   30%   3   15%  11   55%   9   45%
    Bortezomib Refractory
     (n=53)                  1    2%   6   11%  10   19%  17   32%  24   45%
    All Evaluable Patients
     (n=73)                  3    4%  12   16%  13   18%  28   38%  33   45%

Patients who had previously relapsed on a bortezomib-based treatment had a median time to progression (TTP) of 8.5 months. The median TTP for all 73 evaluable study patients (both bortezomib relapsed and refractory) was 6.4 months. As of the report, 16 patients remain on active treatment.

Commenting on the data, Dr. Paul Richardson stated "Perifosine in combination with bortezomib and dexamethasone continues to demonstrate an impressive response rate and time to progression in a heavily pre-treated patient population, with 83% of evaluable patients achieving stable disease or better. Particularly noteworthy is the benefit observed in patients who relapsed on prior bortezomib-based therapy, as reflected by an 8.5 month median time to progression in our study. We continue to be encouraged by the data and look forward to evaluating this combination in a randomized phase 3 trial."

Michael S. Weiss, Chairman and CEO of Keryx Biopharmaceuticals, remarked, "We believe these data confirm the activity of perifosine both in patients who have relapsed following bortezomib therapy and in those patients who were refractory to bort
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Inspiration Biopharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of IB1001 for the Treatment of Hemophilia B
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/pph6hl/united_states ... "United States Medical Adhesives Market Forecast and Opportunities, ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , , , The market ... States is projected to register 9% ... manufacturers across the US are expanding their production ...
(Date:5/28/2015)... May 28, 2015 The Parenteral Drug ... a supporting organization of the Johnson & Johnson ... 2016. Johnson & Johnson (J&J) is ... superbug infections in endoscopes. J&J ran 8 conferences ... 1976 and 2003 on advances in sterilization and ...
(Date:5/28/2015)... Calif. , May 28, 2015 Compassion & ... Committee has approved a bill that would authorize the option ... vote was 5-2. ... (SB 128) , would allow mentally competent adults with six ... medication they could take to painlessly and peacefully end an ...
Breaking Medicine Technology:United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 2United States Medical Adhesives Market Forecast and Opportunities, 2020 - New Medical Innovations with 3M, Henkel Adhesive Research, Ethicon and Cyberbond Dominating 3PDA Announces Support for the Johnson & Johnson Kilmer Conference 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 2California Committee Sends Medical Aid-in-Dying Bill to Senate Floor 3
... Austria, October 20 AFFiRiS AG today announced,that the ... clinical studies of,its two Alzheimer,s vaccines AD01 and AD02, ... a 10 million EUR,milestone payment from licensee GlaxoSmithKline Biologicals. ... in these studies were given four vaccinations,which were well ...
... Oct. 20 /PRNewswire-Asia-FirstCall/ -- Yongye International, Inc.,(Nasdaq: YONG ... distributor of Shengmingsu brand plant and animal nutrient products ... the Company consummated,the restructuring plan required by its September ... Yongye is now a fully integrated manufacturer ...
Cached Medicine Technology:AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimer's Candidate Vaccines Trigger a EUR 10 Million Milestone Payment 2AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimer's Candidate Vaccines Trigger a EUR 10 Million Milestone Payment 3Yongye International Announces Completion of Restructuring 2Yongye International Announces Completion of Restructuring 3
(Date:5/28/2015)... NY (PRWEB) May 28, 2015 The ... Care are proud to present Dr. Alicia Almendral as ... be a big part of the newly opened facility’s ... finest in modern cosmetic treatments. , Dr. Almendral is ... in the latest anti-aging and cosmetic enhancement techniques. Her ...
(Date:5/28/2015)... Los Angeles, Calif. (PRWEB) May 28, 2015 ... announces its selection by ContentChecked (CNCK) as its ... ContentChecked’s latest health and nutrition app, SugarChecked. SugarChecked ... consumers to better understand the potential sugars they ... be responsible for the launch of SugarChecked, execute ...
(Date:5/28/2015)... Success Strategies for Biosimilars Approval:, ... Webinar**, June 23, 2015 — 11:00 a.m. – ... June 23, 2015, FDAnews is offering the combined ... attorneys from the international law firm Duane Morris ... A Roadmap to the 351(k) Application Process. , ...
(Date:5/28/2015)... 2015 Park Cities Pet Sitter is offering ... class starting Saturday, June 6th at 10:30am. The ... McCommas Blvd in Dallas, with a maximum of six dogs ... five weeks, with no class being held over the 4th ... , In this Intermediate-to-Advanced level class, dogs will solidify their ...
(Date:5/28/2015)... 28, 2015 The Boys & Girls Club ... Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ) ... the club can receive much more support as play begins ... A former Boys & Girls Club member and volunteer with ... Ms. Gulbis has accepted the Horizon Blue Cross Blue Shield ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:ContentChecked Selects PMBC Group To Launch New Nutrition App SugarChecked 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 3Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 2Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 3
... Healthy City has raised concern over the high prevalence ... specially females, lower socio-economic and indigenous groups.//,Smoking, which still ... has the dubious distinction of affecting all the systems ... the Shanghai Municipal Center for Disease Prevention and Control ...
... artificial sweeteners got an impetus when a new study ... rat study conducted by Italy’s Ramazzini Institute //is totally ... conducted on aspartame. The U.S. Food & Drug Administration ... in the use of aspartame. The study, to be ...
... that the company is conducting various studies to start producing ... is high worldwide which may lead to a high shortage ... South Africa. ,The South African authorities feel that ... the maximum worldwide production of bird flu vaccines would be ...
... the UK after a successful bypass surgery in Delhi at ... medical tourism.// ,Mavis Childs, 67, waited for more than ... Service (NHS). But she opted for India when the operation ... pain., ,Childs, based in Wombourne, near Wolverhampton, says she ...
... issue of the Journal of the American Geriatrics Society, ... their incidence of falls if they take a vitamin ... vitamin D supplementation can reduce the incidence of falls ... are not classically vitamin D deficient, the Australian researchers ...
... this week’s Australian Medical Journal (AMA) has found that first-time ... of complications if they choose to deliver naturally in subsequent ... The study has found women who have a ... uterine ruptures during birth, post-partum bleeding, infection and hysterectomies than ...
Cached Medicine News:Health News:Aspartame, Artificial Sweetener, A Safe Bet! 2Health News:Aspartame, Artificial Sweetener, A Safe Bet! 3Health News:British Grandmother has timely bypass surgery in India 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: